<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<ReleaseSet Dated="2016-07-04" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" Type="full" xsi:noNamespaceSchemaLocation="http://ftp.ncbi.nlm.nih.gov/pub/clinvar/xsd_public/clinvar_public_1.35.xsd">

<ClinVarSet ID="10310808">
  <RecordStatus>current</RecordStatus>
  <Title>NM_015910.5(WDPCP):c.164G&gt;A (p.Arg55Lys) AND Meckel syndrome, type 6, modifier of</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2016-02-17" ID="57567">
    <ClinVarAccession Acc="RCV000000064" Version="5" Type="RCV" DateUpdated="2016-02-17"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2010-09-10">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>risk factor</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="9727434">
        <Attribute Type="Description">In a patient with Meckel-Gruber syndrome-6 (MKS6; 612284), Kim et al. (2010) identified heterozygosity for an arginine-to-leucine substitution at codon 55 of the WDPCP gene (R55K). The mutation arose from a 164G-A transition. This patient was also compound heterozygous for mutations in the CC2D2A gene (612013).</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">20671153</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="47">
      <Measure Type="single nucleotide variant" ID="15086">
        <Name>
          <ElementValue Type="Preferred">NM_015910.5(WDPCP):c.164G&gt;A (p.Arg55Lys)</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="HGVS, coding, RefSeq" Change="c.164G&gt;A">NM_015910.5:c.164G&gt;A</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="HGVS, genomic, RefSeqGene" Change="g.106243G&gt;A">NG_028144.1:g.106243G&gt;A</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="HGVS, genomic, top level" Change="g.63487491C&gt;T" integerValue="38">NC_000002.12:g.63487491C&gt;T</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="HGVS, genomic, top level, previous" Change="g.63714625C&gt;T" integerValue="37">NC_000002.11:g.63714625C&gt;T</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="HGVS, protein, RefSeq" Change="p.Arg55Lys">NP_056994.3:p.Arg55Lys</Attribute>
          <XRef Type="rs" ID="267606693" DB="dbSNP"/>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="MolecularConsequence">missense variant</Attribute>
          <XRef ID="SO:0001583" DB="Sequence Ontology"/>
          <XRef ID="NM_015910.5:c.164G&gt;A" DB="RefSeq"/>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="ProteinChange1LetterCode">R55K</Attribute>
          <XRef Type="Allelic variant" ID="613580.0003" DB="OMIM"/>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="ProteinChange3LetterCode">ARG55LYS</Attribute>
          <XRef Type="Allelic variant" ID="613580.0003" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>2p15</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.28" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="63487491" stop="63487491" display_start="63487491" display_stop="63487491" variantLength="1" referenceAllele="C" alternateAllele="T"/>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="63714625" stop="63714625" display_start="63714625" display_stop="63714625" variantLength="1" referenceAllele="C" alternateAllele="T"/>
        <MeasureRelationship Type="variant in gene">
          <Name>
            <ElementValue Type="Preferred">WD repeat containing planar cell polarity effector</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">WDPCP</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.28" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="63120761" stop="63840824" display_start="63120761" display_stop="63840824" variantLength="467351" Strand="-"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="63348517" stop="63815866" display_start="63348517" display_stop="63815866" variantLength="467350" Strand="-"/>
          <XRef ID="51057" DB="Gene"/>
          <XRef Type="MIM" ID="613580" DB="OMIM"/>
          <XRef ID="HGNC:28027" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="613580.0003" DB="OMIM"/>
        <XRef Type="rs" ID="267606693" DB="dbSNP"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">NM_015910.5(WDPCP):c.164G&gt;A (p.Arg55Lys)</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="24">
      <Trait ID="9596" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Meckel syndrome, type 6, modifier of</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="20207">
    <ClinVarSubmissionID localKey="613580.0003_MECKEL SYNDROME, TYPE 6, MODIFIER OF" submitter="OMIM" submitterDate="2014-10-24" title="WDPCP, ARG55LYS _MECKEL SYNDROME, TYPE 6, MODIFIER OF"/>
    <ClinVarAccession Acc="SCV000020207" Version="3" Type="SCV" OrgID="3" DateUpdated="2015-10-11"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2010-09-10">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>risk factor</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="613580.0003" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In a patient with Meckel-Gruber syndrome-6 (MKS6; 612284), Kim et al. (2010) identified heterozygosity for an arginine-to-leucine substitution at codon 55 of the WDPCP gene (R55K). The mutation arose from a 164G-A transition. This patient was also compound heterozygous for mutations in the CC2D2A gene (612013).</Attribute>
        <Citation>
          <ID Source="PubMed">20671153</ID>
        </Citation>
        <XRef DB="OMIM" ID="612284" Type="MIM"/>
        <XRef DB="OMIM" ID="612013" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">WDPCP, ARG55LYS</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">ARG55LYS</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">WDPCP</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="613580.0003" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">MECKEL SYNDROME, TYPE 6, MODIFIER OF</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="10310812">
  <RecordStatus>current</RecordStatus>
  <Title>NM_022098.3(XPNPEP3):c.1357G&gt;T (p.Gly453Cys) AND Nephronophthisis-like nephropathy 1</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2016-02-17" ID="57571">
    <ClinVarAccession Acc="RCV000000068" Version="3" Type="RCV" DateUpdated="2016-02-17"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2010-03-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="9727354">
        <Attribute Type="Description">In 3 affected sibs of a consanguineous Finnish family with nephronophthisis-like nephropathy-1 (NPHPL1; 613159), O'Toole et al. (2010) identified a homozygous 1357G-T transversion in the last base of exon 9 of the XPNPEP3 gene, resulting in a gly453-to-cys (G453C) substitution in a highly conserved residue. The mutation occurs in an 80% conserved exonic simplePosition of the splice donor consensus sequence, and RT-PCR from lymphoblastoid cells showed that the G453C mutation disrupted correct splicing by activating a cryptic splice site, adding 31 nucleotides from intron 9, and introducing a frameshift that resulted in premature termination in exon 10. There was also a faint band at the size of the wildtype splice product, suggesting some residual correct splicing. The mutation was not found in 118 Western European controls but was found in 1 of 100 Finnish controls. Haplotype analysis suggested a founder effect. All 3 patients developed moderate renal insufficiency (glomerular filtration rate at 30-40% of normal) between 20 and 29 years of age. Renal biopsies showed characteristic features of nephronophthisis, such as thickening, splitting, and attenuation of the tubular basement membrane, atrophic tubules, and mild interstitial fibrosis. Renal ultrasound revealed increased echogenicity in 3 and cysts in 2. All had hypertension. Extrarenal features included essential tremor in 3, high frequency sensorineural hearing loss in 2, and arachnoid cysts on brain imaging in 1. Two also had gout. Skeletal muscle mitochondrial respiratory activity was normal.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">20179356</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="51">
      <Measure Type="single nucleotide variant" ID="15090">
        <Name>
          <ElementValue Type="Preferred">NM_022098.3(XPNPEP3):c.1357G&gt;T (p.Gly453Cys)</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="HGVS, coding, RefSeq" Change="c.1357G&gt;T">NM_022098.3:c.1357G&gt;T</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="HGVS, genomic, RefSeqGene" Change="g.72402G&gt;T">NG_028221.1:g.72402G&gt;T</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="HGVS, genomic, top level" Change="g.40924482G&gt;T" integerValue="38">NC_000022.11:g.40924482G&gt;T</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="HGVS, genomic, top level, previous" Change="g.41320486G&gt;T" integerValue="37">NC_000022.10:g.41320486G&gt;T</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="HGVS, protein, RefSeq" Change="p.Gly453Cys">NP_071381.1:p.Gly453Cys</Attribute>
          <XRef Type="rs" ID="267607179" DB="dbSNP"/>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="MolecularConsequence">missense variant</Attribute>
          <XRef ID="SO:0001583" DB="Sequence Ontology"/>
          <XRef ID="NM_022098.3:c.1357G&gt;T" DB="RefSeq"/>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="ProteinChange1LetterCode">G453C</Attribute>
          <XRef Type="Allelic variant" ID="613553.0001" DB="OMIM"/>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="ProteinChange3LetterCode">GLY453CYS</Attribute>
          <XRef Type="Allelic variant" ID="613553.0001" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>22q13.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.28" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="40924482" stop="40924482" display_start="40924482" display_stop="40924482" variantLength="1" referenceAllele="G" alternateAllele="T"/>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="41320486" stop="41320486" display_start="41320486" display_stop="41320486" variantLength="1" referenceAllele="G" alternateAllele="T"/>
        <MeasureRelationship Type="variant in gene">
          <Name>
            <ElementValue Type="Preferred">X-prolyl aminopeptidase 3, mitochondrial</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">XPNPEP3</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.28" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="40857080" stop="40932818" display_start="40857080" display_stop="40932818" variantLength="75739" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="41253084" stop="41328822" display_start="41253084" display_stop="41328822" variantLength="75739" Strand="+"/>
          <XRef ID="63929" DB="Gene"/>
          <XRef Type="MIM" ID="613553" DB="OMIM"/>
          <XRef ID="HGNC:28052" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="613553.0001" DB="OMIM"/>
        <XRef Type="rs" ID="267607179" DB="dbSNP"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">NM_022098.3(XPNPEP3):c.1357G&gt;T (p.Gly453Cys)</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="26">
      <Trait ID="9598" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Nephronophthisis-like nephropathy 1</ElementValue>
          <XRef ID="Nephronophthisis-like+nephropathy+1/8986" DB="Genetic Alliance"/>
        </Name>
        <Symbol>
          <ElementValue Type="Preferred">NPHPL1</ElementValue>
          <XRef Type="MIM" ID="613159" DB="OMIM"/>
        </Symbol>
        <AttributeSet>
          <Attribute Type="public definition">Nephronophthisis is an autosomal recessive cystic kidney disease  characterized by onset of end-stage renal failure in the first 3 decades of life. The disorder is often associated with extrarenal manifestations, including liver fibrosis, retinal degeneration, and central nervous system abnormalities (summary by O'Toole et al., 2010).&#13;For a general phenotypic description and a discussion of genetic heterogeneity of nephronophthisis, see NPHP1 (256100).</Attribute>
          <XRef Type="MIM" ID="613159" DB="OMIM"/>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="age of onset">All ages</Attribute>
          <XRef ID="655" DB="Orphanet"/>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="prevalence">1-9 / 100 000</Attribute>
          <XRef ID="655" DB="Orphanet"/>
        </AttributeSet>
        <XRef ID="C3150419" DB="MedGen"/>
        <XRef ID="655" DB="Orphanet"/>
        <XRef Type="MIM" ID="613159" DB="OMIM"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="20211">
    <ClinVarSubmissionID localKey="613553.0001_NEPHRONOPHTHISIS-LIKE NEPHROPATHY 1" submitter="OMIM" submitterDate="2013-09-06" title="XPNPEP3, GLY453CYS  _NEPHRONOPHTHISIS-LIKE NEPHROPATHY 1"/>
    <ClinVarAccession Acc="SCV000020211" Version="2" Type="SCV" OrgID="3" DateUpdated="2015-10-11"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2010-03-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="613553.0001" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In 3 affected sibs of a consanguineous Finnish family with nephronophthisis-like nephropathy-1 (NPHPL1; 613159), O'Toole et al. (2010) identified a homozygous 1357G-T transversion in the last base of exon 9 of the XPNPEP3 gene, resulting in a gly453-to-cys (G453C) substitution in a highly conserved residue. The mutation occurs in an 80% conserved exonic simplePosition of the splice donor consensus sequence, and RT-PCR from lymphoblastoid cells showed that the G453C mutation disrupted correct splicing by activating a cryptic splice site, adding 31 nucleotides from intron 9, and introducing a frameshift that resulted in premature termination in exon 10. There was also a faint band at the size of the wildtype splice product, suggesting some residual correct splicing. The mutation was not found in 118 Western European controls but was found in 1 of 100 Finnish controls. Haplotype analysis suggested a founder effect. All 3 patients developed moderate renal insufficiency (glomerular filtration rate at 30-40% of normal) between 20 and 29 years of age. Renal biopsies showed characteristic features of nephronophthisis, such as thickening, splitting, and attenuation of the tubular basement membrane, atrophic tubules, and mild interstitial fibrosis. Renal ultrasound revealed increased echogenicity in 3 and cysts in 2. All had hypertension. Extrarenal features included essential tremor in 3, high frequency sensorineural hearing loss in 2, and arachnoid cysts on brain imaging in 1. Two also had gout. Skeletal muscle mitochondrial respiratory activity was normal.</Attribute>
        <Citation>
          <ID Source="PubMed">20179356</ID>
        </Citation>
        <XRef DB="OMIM" ID="613159" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">XPNPEP3, GLY453CYS</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">GLY453CYS</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">XPNPEP3</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="613553.0001" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">NEPHRONOPHTHISIS-LIKE NEPHROPATHY 1</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

<ClinVarSet ID="10310813">
  <RecordStatus>current</RecordStatus>
  <Title>XPNPEP3, 4-BP DEL, 931AACA AND Nephronophthisis-like nephropathy 1</Title>
  <ReferenceClinVarAssertion DateCreated="2012-08-13" DateLastUpdated="2016-02-17" ID="57572">
    <ClinVarAccession Acc="RCV000000069" Version="3" Type="RCV" DateUpdated="2016-02-17"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2010-03-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species TaxonomyId="9606">human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData ID="9727512">
        <Attribute Type="Description">In 2 affected sibs from a consanguineous Turkish family with nephronophthisis-like nephropathy-1 (NPHPL1; 613159), O'Toole et al. (2010) identified a homozygous 4-bp deletion (931delAACA) in exon 6 of the XPNPEP3 gene, resulting in premature termination within the predicted prolidase domain, which is the catalytic domain. The mutation was not found in 150 European controls or in 83 Turkish controls. The mutation was predicted to result in complete loss of protein function. The patients had a severe disorder, with end-stage renal disease by 8 and 9 years of age, respectively. Renal ultrasound and renal histology demonstrated nephronophthisis. In addition, both affected individuals showed a mitochondrial disorder, with isolated complex I deficiency activity in muscle and had seizures, mental retardation, and hypertrophic dilated cardiomyopathy. One had chronic pancreatitis with pancreatic cysts, while the other had hepatic involvement.</Attribute>
        <Citation Type="general">
          <ID Source="PubMed">20179356</ID>
        </Citation>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant" ID="52">
      <Measure Type="Deletion" ID="15091">
        <Name>
          <ElementValue Type="Preferred">XPNPEP3, 4-BP DEL, 931AACA</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="nucleotide change">4-BP DEL, 931AACA</Attribute>
          <XRef Type="Allelic variant" ID="613553.0002" DB="OMIM"/>
        </AttributeSet>
        <CytogeneticLocation>22q13.31-q13.33</CytogeneticLocation>
        <MeasureRelationship Type="variant in gene">
          <Name>
            <ElementValue Type="Preferred">X-prolyl aminopeptidase 3, mitochondrial</ElementValue>
          </Name>
          <Symbol>
            <ElementValue Type="Preferred">XPNPEP3</ElementValue>
          </Symbol>
          <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.28" AssemblyStatus="current" Chr="10" Accession="NC_000022.11" start="40857080" stop="40932818" display_start="40857080" display_stop="40932818" variantLength="75739" Strand="+"/>
          <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="10" Accession="NC_000022.10" start="41253084" stop="41328822" display_start="41253084" display_stop="41328822" variantLength="75739" Strand="+"/>
          <XRef ID="63929" DB="Gene"/>
          <XRef Type="MIM" ID="613553" DB="OMIM"/>
          <XRef ID="HGNC:28052" DB="HGNC"/>
        </MeasureRelationship>
        <XRef Type="Allelic variant" ID="613553.0002" DB="OMIM"/>
      </Measure>
      <Name>
        <ElementValue Type="Preferred">XPNPEP3, 4-BP DEL, 931AACA</ElementValue>
      </Name>
    </MeasureSet>
    <TraitSet Type="Disease" ID="26">
      <Trait ID="9598" Type="Disease">
        <Name>
          <ElementValue Type="Preferred">Nephronophthisis-like nephropathy 1</ElementValue>
          <XRef ID="Nephronophthisis-like+nephropathy+1/8986" DB="Genetic Alliance"/>
        </Name>
        <Symbol>
          <ElementValue Type="Preferred">NPHPL1</ElementValue>
          <XRef Type="MIM" ID="613159" DB="OMIM"/>
        </Symbol>
        <AttributeSet>
          <Attribute Type="public definition">Nephronophthisis is an autosomal recessive cystic kidney disease  characterized by onset of end-stage renal failure in the first 3 decades of life. The disorder is often associated with extrarenal manifestations, including liver fibrosis, retinal degeneration, and central nervous system abnormalities (summary by O'Toole et al., 2010).&#13;For a general phenotypic description and a discussion of genetic heterogeneity of nephronophthisis, see NPHP1 (256100).</Attribute>
          <XRef Type="MIM" ID="613159" DB="OMIM"/>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="age of onset">All ages</Attribute>
          <XRef ID="655" DB="Orphanet"/>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="prevalence">1-9 / 100 000</Attribute>
          <XRef ID="655" DB="Orphanet"/>
        </AttributeSet>
        <XRef ID="C3150419" DB="MedGen"/>
        <XRef ID="655" DB="Orphanet"/>
        <XRef Type="MIM" ID="613159" DB="OMIM"/>
      </Trait>
    </TraitSet>
  </ReferenceClinVarAssertion>
  <ClinVarAssertion ID="20212">
    <ClinVarSubmissionID localKey="613553.0002_NEPHRONOPHTHISIS-LIKE NEPHROPATHY 1" submitter="OMIM" submitterDate="2013-09-06" title="XPNPEP3, 4-BP DEL, 931AACA  _NEPHRONOPHTHISIS-LIKE NEPHROPATHY 1"/>
    <ClinVarAccession Acc="SCV000020212" Version="2" Type="SCV" OrgID="3" DateUpdated="2015-10-11"/>
    <RecordStatus>current</RecordStatus>
    <ClinicalSignificance DateLastEvaluated="2010-03-01">
      <ReviewStatus>no assertion criteria provided</ReviewStatus>
      <Description>Pathogenic</Description>
    </ClinicalSignificance>
    <Assertion Type="variation to disease"/>
    <ExternalID DB="OMIM" ID="613553.0002" Type="Allelic variant"/>
    <ObservedIn>
      <Sample>
        <Origin>germline</Origin>
        <Species>human</Species>
        <AffectedStatus>not provided</AffectedStatus>
      </Sample>
      <Method>
        <MethodType>literature only</MethodType>
      </Method>
      <ObservedData>
        <Attribute Type="Description">In 2 affected sibs from a consanguineous Turkish family with nephronophthisis-like nephropathy-1 (NPHPL1; 613159), O'Toole et al. (2010) identified a homozygous 4-bp deletion (931delAACA) in exon 6 of the XPNPEP3 gene, resulting in premature termination within the predicted prolidase domain, which is the catalytic domain. The mutation was not found in 150 European controls or in 83 Turkish controls. The mutation was predicted to result in complete loss of protein function. The patients had a severe disorder, with end-stage renal disease by 8 and 9 years of age, respectively. Renal ultrasound and renal histology demonstrated nephronophthisis. In addition, both affected individuals showed a mitochondrial disorder, with isolated complex I deficiency activity in muscle and had seizures, mental retardation, and hypertrophic dilated cardiomyopathy. One had chronic pancreatitis with pancreatic cysts, while the other had hepatic involvement.</Attribute>
        <Citation>
          <ID Source="PubMed">20179356</ID>
        </Citation>
        <XRef DB="OMIM" ID="613159" Type="MIM"/>
      </ObservedData>
    </ObservedIn>
    <MeasureSet Type="Variant">
      <Measure Type="Variation">
        <Name>
          <ElementValue Type="Preferred">XPNPEP3, 4-BP DEL, 931AACA</ElementValue>
        </Name>
        <AttributeSet>
          <Attribute Type="NonHGVS">4-BP DEL, 931AACA</Attribute>
        </AttributeSet>
        <MeasureRelationship Type="variant in gene">
          <Symbol>
            <ElementValue Type="Preferred">XPNPEP3</ElementValue>
          </Symbol>
        </MeasureRelationship>
        <XRef DB="OMIM" ID="613553.0002" Type="Allelic variant"/>
      </Measure>
    </MeasureSet>
    <TraitSet Type="Disease">
      <Trait Type="Disease">
        <Name>
          <ElementValue Type="Preferred">NEPHRONOPHTHISIS-LIKE NEPHROPATHY 1</ElementValue>
        </Name>
      </Trait>
    </TraitSet>
  </ClinVarAssertion>
</ClinVarSet>

</ReleaseSet>
